Tolaney SM, Im YH, Calvo E, Lu YS, et al. Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K-Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. Clin Cancer Res 2020 Sep 4. pii: 1078-0432.CCR-20-0645.
PMID: 32887722